Clinical Cancer Investigation Journal

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 10  |  Issue : 1  |  Page : 5--10

Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran


Ramin Shekarriz, Akbar Hedayatizadeh-Omran, Omolbanin Amjadi, Reza Alizadeh-Navaei, Gholamali Godazandeh 
 Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

Correspondence Address:
Akbar Hedayatizadeh-Omran
Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari
Iran

Background: Gastric cancer is one of the most common cancers in the world. Programmed death-ligand 1 (PD-L1) is the main ligand of the programmed death-1 receptor that plays a key role in apoptosis in patients with gastric cancer. Materials and Methods: In this study, forty gastric cancer patients and forty healthy controls were enrolled. Serum PD-L1 was measured by enzyme-linked immunosorbent assay. Results: The mean (interquartile range) value of expression level of PD-L1 was 70.6 (36.6–127.3) in patients and 47.7 (29.9–92.1) in controls. There were no significant differences in PD-L1 expression between the two groups and tumor characteristics, but there was a statistically significant difference between the high expression level of PD-L1 and gastric cancer development (P = 0.044, odds ratio = 2.77, 95% confidence interval = 1.12–6.86). Conclusions: PD-L1 level increases in gastric cancer patients, so it could be used as a predictor factor.


How to cite this article:
Shekarriz R, Hedayatizadeh-Omran A, Amjadi O, Alizadeh-Navaei R, Godazandeh G. Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran.Clin Cancer Investig J 2021;10:5-10


How to cite this URL:
Shekarriz R, Hedayatizadeh-Omran A, Amjadi O, Alizadeh-Navaei R, Godazandeh G. Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran. Clin Cancer Investig J [serial online] 2021 [cited 2021 Mar 5 ];10:5-10
Available from: https://www.ccij-online.org/article.asp?issn=2278-0513;year=2021;volume=10;issue=1;spage=5;epage=10;aulast=Shekarriz;type=0